Literature DB >> 30066223

Highlights from the 2018 American College of Cardiology scientific session in Orlando, Florida.

Dylan L Steen1.   

Abstract

Year:  2018        PMID: 30066223     DOI: 10.1007/s11239-018-1716-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  6 in total

1.  Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure.

Authors:  Mandeep R Mehra; Daniel J Goldstein; Nir Uriel; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Gregory A Ewald; Akinobu Itoh; David Dean; Arun Krishnamoorthy; William G Cotts; Antone J Tatooles; Ulrich P Jorde; Brian A Bruckner; Jerry D Estep; Valluvan Jeevanandam; Gabriel Sayer; Douglas Horstmanshof; James W Long; Sanjeev Gulati; Eric R Skipper; John B O'Connell; Gerald Heatley; Poornima Sood; Yoshifumi Naka
Journal:  N Engl J Med       Date:  2018-03-11       Impact factor: 91.245

2.  A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops.

Authors:  Ronald G Victor; Kathleen Lynch; Ning Li; Ciantel Blyler; Eric Muhammad; Joel Handler; Jeffrey Brettler; Mohamad Rashid; Brent Hsu; Davontae Foxx-Drew; Norma Moy; Anthony E Reid; Robert M Elashoff
Journal:  N Engl J Med       Date:  2018-03-12       Impact factor: 91.245

3.  Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.

Authors:  Steven R Steinhubl; Rajesh R Mehta; Gail S Ebner; Marissa M Ballesteros; Jill Waalen; Gregory Steinberg; Percy Van Crocker; Elise Felicione; Chureen T Carter; Shawn Edmonds; Joseph P Honcz; Gines Diego Miralles; Dimitri Talantov; Troy C Sarich; Eric J Topol
Journal:  Am Heart J       Date:  2016-02-23       Impact factor: 4.749

4.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Authors:  Gregory G Schwartz; Laurence Bessac; Lisa G Berdan; Deepak L Bhatt; Vera Bittner; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Matthew T Roe; Tyrus Rorick; William J Sasiela; Cheerag Shirodaria; Michael Szarek; Jean-François Tamby; Pierluigi Tricoci; Harvey White; Andreas Zeiher; Philippe Gabriel Steg
Journal:  Am Heart J       Date:  2014-08-07       Impact factor: 4.749

5.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.